TY - JOUR
T1 - Werner's syndrome as a hereditary risk factor for exocrine pancreatic cancer
T2 - Potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy
AU - Chun, Stephen G.
AU - Yee, Nelson S.
N1 - Funding Information:
We wish to express our gratitude to the family of our reported patient for granting us permission to contribute this case to the medical literature and to establish a cell line. We thank Dr. Peter Bryant-Greenwood (University of Hawaii) for valuable discussion during the preparation of this manuscript. This work was supported by research grant 123-6260-4 from the Cancer Research Center of Hawaii of the University of Hawaii (S.G.C.), the Pilot Grant in Translational Research from the Department of Internal Medicine of the University of Iowa Carver College of Medicine (N.S.Y.), the Cancer Center Designated Gift Fund for pancreatic cancer research (N.S.Y.) and the Cancer Center Support Grant (P30 CA 086862) by the National Cancer Institute to the Holden Comprehensive Cancer Center at the University of Iowa (N.S.Y.).
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Advanced age is considered a risk factor of pancreatic cancer, but this relationship at the molecular and genetic level remains unclear. We present a clinical case series focusing on an association between pancreatic adenocarcinoma and Werner's syndrome (WS) that is an autosomal recessive genetic disorder characterized by accelerated aging and cancer predisposition, and is caused by loss-of-function mutations in the WS RecQ helicase gene (WRN). Although pancreatic adenocarcinoma mostly occurs in a sporadic fashion, a minority of cases occurs in the context of susceptible individuals with hereditary syndromes. While WS has not been previously recognized as a risk factor for developing malignant tumors of the exocrine pancreas, the clinicopathologic features of three reported patients suggest a contributory role of WRN deficiency in pancreatic carcinogenesis. Molecular genetic analyses support the role of WRN as a tumor suppressor gene, although recent evidence reveals that WRN can alternatively promote oncogenicity depending on the molecular context. Based upon the clinico-pathologic features of these patients and the role of WRN in experimental models, we propose that its loss-of-function predisposes the development of pancreatic adenocarcinoma through epigenetic silencing or loss-of-heterozygosity of WRN. To test this hypothesis, we are investigating the mechanistic role of WRN in pancreatic cancer models including a pancreatic adenocarcinoma cell line generated from a human with WS. These studies are expected to provide new insight into the relationship between aging and pancreatic tumorigenesis, and facilitate development of novel strategies for patient-tailored interventions in this deadly malignancy.
AB - Advanced age is considered a risk factor of pancreatic cancer, but this relationship at the molecular and genetic level remains unclear. We present a clinical case series focusing on an association between pancreatic adenocarcinoma and Werner's syndrome (WS) that is an autosomal recessive genetic disorder characterized by accelerated aging and cancer predisposition, and is caused by loss-of-function mutations in the WS RecQ helicase gene (WRN). Although pancreatic adenocarcinoma mostly occurs in a sporadic fashion, a minority of cases occurs in the context of susceptible individuals with hereditary syndromes. While WS has not been previously recognized as a risk factor for developing malignant tumors of the exocrine pancreas, the clinicopathologic features of three reported patients suggest a contributory role of WRN deficiency in pancreatic carcinogenesis. Molecular genetic analyses support the role of WRN as a tumor suppressor gene, although recent evidence reveals that WRN can alternatively promote oncogenicity depending on the molecular context. Based upon the clinico-pathologic features of these patients and the role of WRN in experimental models, we propose that its loss-of-function predisposes the development of pancreatic adenocarcinoma through epigenetic silencing or loss-of-heterozygosity of WRN. To test this hypothesis, we are investigating the mechanistic role of WRN in pancreatic cancer models including a pancreatic adenocarcinoma cell line generated from a human with WS. These studies are expected to provide new insight into the relationship between aging and pancreatic tumorigenesis, and facilitate development of novel strategies for patient-tailored interventions in this deadly malignancy.
UR - http://www.scopus.com/inward/record.url?scp=77957163485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957163485&partnerID=8YFLogxK
U2 - 10.4161/cbt.10.5.12763
DO - 10.4161/cbt.10.5.12763
M3 - Article
C2 - 20657174
AN - SCOPUS:77957163485
SN - 1538-4047
VL - 10
SP - 430
EP - 437
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 5
ER -